0001104659-21-033558.txt : 20210309 0001104659-21-033558.hdr.sgml : 20210309 20210309090140 ACCESSION NUMBER: 0001104659-21-033558 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210304 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210309 DATE AS OF CHANGE: 20210309 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc. CENTRAL INDEX KEY: 0000850261 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330344842 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36150 FILM NUMBER: 21724215 BUSINESS ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-203-4100 MAIL ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC DATE OF NAME CHANGE: 19920703 8-K 1 tm219070d1_8k.htm FORM 8-K
0000850261 false 0000850261 2021-03-04 2021-03-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 4, 2021

 

 

SORRENTO THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware   001-36150   33-0344842

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

4955 Directors Place

San Diego, CA 92121

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (858) 203-4100

 

N/A

(Former Name, or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered pursuant to Section 12(b) of the Act:

 

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value   SRNE   The Nasdaq Stock Market LLC

 

 

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

  

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Exclusive License Agreement

 

On March 4, 2021, Sorrento Therapeutics, Inc. (the “Company”) entered into an exclusive license agreement (the “License Agreement”) with Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the License Agreement, among other things, Mount Sinai granted the Company a worldwide, exclusive, sublicensable license to certain of Mount Sinai’s patents and monoclonal antibodies and a worldwide, non-exclusive, sublicensable license to certain of Mount Sinai’s technical information to develop, manufacture, commercialize, and exploit related products and services (“Licensed Products”) for all fields, uses, and applications, including for the diagnosis, prevention, treatment, and cure of coronavirus.

 

As consideration for the license under the License Agreement, the Company agreed to (i) enter into a stock purchase agreement to sell the Shares (as defined below) to Mount Sinai, and (ii) pay to Mount Sinai certain milestone payments upon the achievement of certain clinical trial and regulatory milestones.

 

The Company will also pay Mount Sinai royalties in the low-single digit to mid-single digit percentages of annual net sales of Licensed Products by the Company and a share of any sublicense revenue received by the Company from sublicensees.

 

The foregoing summary of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement. A copy of the License Agreement will be filed with the Securities and Exchange Commission (the “SEC”) as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2021 (the “Form 10-Q”) or via an amendment to this Current Report on Form 8-K. Certain terms of the License Agreement have been omitted from this Current Report on Form 8-K and will be omitted from the version of the License Agreement to be filed as an exhibit to the Form 10-Q or via an amendment to this Current Report on Form 8-K pursuant to Item 601(b)(10) of Regulation S-K because such terms are both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed.

 

The representations, warranties and covenants contained in the License Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the License Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the License Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the License Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.

 

Stock Purchase Agreement

 

In connection with the License Agreement, on March 4, 2021, the Company and Mount Sinai also entered into a Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell to Mount Sinai a number of shares of its Common Stock (the “Shares”) equal to the quotient of (a) $7.5 million divided by (b) the Price Per Share (as defined below). The Price Per Share shall be the lower of (i) the closing price per shares of the Common Stock on the date of the Purchase Agreement and (ii) the weighted average closing price of the Common Stock, as reported on The Nasdaq Stock Market LLC, for the 11 consecutive trading days beginning on the fifth trading day prior to the date of the Purchase Agreement and ending on the fifth trading day following the date of the Purchase Agreement.

 

The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.

 

The foregoing summary of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which will be filed with the SEC as an exhibit to the Form 10-Q or via an amendment to this Current Report on Form 8-K.

 

 

 

 

Registration Rights Agreement

 

In connection with the License Agreement, on March 4, 2021, the Company and Mount Sinai also entered into a Registration Rights Agreement (the “Registration Rights Agreement”), pursuant to which the Company agreed to file and keep effective one or more registration statements (the “Registration Statements”) with the SEC under the Securities Act of 1933, as amended, relating to the resale by Mount Sinai of the Shares. Under the Registration Rights Agreement, the Company is required to file such Registration Statements with the SEC within 60 days following the date on which the Shares are issued to Mount Sinai.

 

The foregoing summary of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, which will be filed with the SEC as an exhibit to the Form 10-Q or via an amendment to this Current Report on Form 8-K.

 

Item 8.01. Other Events.

 

On March 9, 2021, the Company issued a press release announcing its entry into the License Agreement. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

99.1 Press Release, dated March 9, 2021.
104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SORRENTO THERAPEUTICS, INC.
     
Date:  March 9, 2021 By: /s/ Henry Ji, Ph.D.
    Name:  Henry Ji, Ph.D.
    Title: Chairman of the Board, President and Chief Executive Officer

 

 

 

 EX-99.1 2 tm219070d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

  FOR IMMEDIATE RELEASE

 

March 9, 2021

 

SORRENTO AND MOUNT SINAI HEALTH SYSTEM ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT OF POTENT ANTIBODY COMBINATIONS AIMED AT NEUTRALIZING SARS-CoV-2 AND THE EMERGING UNITED KINGDOM AND SOUTH AFRICA VARIANTS OF COVID-19

 

·Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well as current variants of concern.

 

·Pre-clinical development of an antibody combination therapeutic including Sorrento and Mount Sinai antibodies for intravenous (IV) and intranasal administration is underway.

 

·This step in the fight against COVID-19 follows the progress made with Sorrento’s intravenous STI-2020 (COVI-AMGTM) that completed Phase 1 safety studies in healthy volunteers and is now in Phase 2 studies for mild to moderate COVID-19 patients in outpatient and inpatient settings; and Sorrento’s intranasal STI-2099 (COVIDROPSTM) that is being tested in Phase 1 studies in healthy volunteers and mild to moderate COVID-19 patients.

 

SAN DIEGO, March 9, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai (“Mount Sinai”). Sorrento and Mount Sinai have entered into an Exclusive License Agreement for a collection of antibodies having SARS-CoV-2 neutralizing properties that were developed by Mount Sinai.

 

The license also contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized monoclonal antibodies for therapeutic applications.

 

COVISHIELD, which is under development, will be a combination of two monoclonal antibodies designed to protect against disease caused by existing and emerging variants of SARS-CoV-2. Using the early pandemic variants as well as the emerging variants of concern (“VOCs”) that have increased in prevalence globally through the course of the pandemic, Sorrento identified candidate monoclonal antibody combinations, or “cocktails”, with potent activity against the breadth of these VOCs, including the United Kingdom (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants. Positive results from these laboratory studies are expected to support the future research path and FDA evaluation of COVISHIELD.

 

 

 

 

COVISHIELD represents a coordination of the discovery and development resources of Sorrento, incorporating intellectual property developed by Mount Sinai, in order to provide a rapid and dynamic means of responding to changes in the public health burden posed by coronaviruses and similar pandemic threat pathogens. Sorrento is developing capabilities and solutions with a goal of contributing to pandemic readiness.

 

Sorrento Chairman and CEO, Dr. Henry Ji, commented, “We are pleased with the excellent COVISHIELD antibody candidates identified thus far, and we at Sorrento are committed to rapidly developing the COVISHIELD cocktail against known and emerging COVID-19 variants of concern. Sorrento looks forward to future collaborations with the respected research capabilities of Mount Sinai centered on the development of innovative anti-viral and anti-cancer therapeutic candidates.”

 

About Sorrento Therapeutics, Inc.

 

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

 

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

 

For more information visit www.sorrentotherapeutics.com.

 

 

 

 

Forward-Looking Statements

 

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the neutralizing capabilities of COVISHIELD antibody combinations and potential effectiveness against COVID-19 and any variants of the disease; the therapeutic potential of COVISHIELD for SARS-CoV-2 and COVID-19 disease; the potential clinical relevance and/or significance of clinical studies of STI-2020 and STI-2099; any future agreements or collaborations that may be entered into or occur, respectively, between Sorrento and Mount Sinai; the efficacy of candidate monoclonal antibody combinations against Sars-CoV-2 and any emerging variants of concern; expectations regarding results of laboratory studies of COVISHIELD, and the potential for any results to support the future research path and FDA evaluation of COVISHIELD; Sorrento’s and Mount Sinai’s ability to provide a rapid and dynamic means of responding to changes in public health burden posed by coronaviruses and similar pandemic threat pathogens; expectations regarding Sorrento’s development of capabilities and solutions to contribute to pandemic readiness; Sorrento’s commitment to rapidly developing and commercializing COVISHIELD against known and emerging COVID-19 variants of concern; and Sorrento’s potential position in the diagnostics testing and therapeutics industries. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates’ and partners’ technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical and clinical studies and seeking regulatory approval for COVISHIELD, including the timing for receipt of any such approval; conducting and receiving results of clinical trials; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

 

# # #

 

Contact

Alexis Nahama, DVM (SVP Corporate Development)

Email: mediarelations@sorrentotherapeutics.com

 

# # #

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

 

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

 

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

 

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

 

All other trademarks are the property of their respective owners.

 

©2021 Sorrento Therapeutics, Inc. All Rights Reserved.

 

 

 

 EX-101.SCH 3 srne-20210304.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 srne-20210304_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 srne-20210304_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm219070d1_ex99-1img01.jpg GRAPHIC begin 644 tm219070d1_ex99-1img01.jpg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end XML 7 tm219070d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000850261 2021-03-04 2021-03-04 iso4217:USD shares iso4217:USD shares 0000850261 false 8-K 2021-03-04 SORRENTO THERAPEUTICS, INC. DE 001-36150 33-0344842 4955 Directors Place San Diego CA 92121 858 203-4100 false false false false Common Stock, $0.0001 par value SRNE NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Mar. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 04, 2021
Entity File Number 001-36150
Entity Registrant Name SORRENTO THERAPEUTICS, INC.
Entity Central Index Key 0000850261
Entity Tax Identification Number 33-0344842
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4955 Directors Place
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 203-4100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol SRNE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sorrentotherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm219070d1_8k.htm srne-20210304.xsd srne-20210304_lab.xml srne-20210304_pre.xml tm219070d1_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm219070d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm219070d1_8k.htm" ] }, "labelLink": { "local": [ "srne-20210304_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "srne-20210304_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "srne-20210304.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "srne", "nsuri": "http://sorrentotherapeutics.com/20210304", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm219070d1_8k.htm", "contextRef": "From2021-03-04to2021-03-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://sorrentotherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm219070d1_8k.htm", "contextRef": "From2021-03-04to2021-03-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://sorrentotherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001104659-21-033558-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-033558-xbrl.zip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̚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end